	US 12,419,916 B2
	Bone derived fibers and oxygenated wound treatments
Andrew J. Carter, Sherman Oaks, CA (US); Bradley E. Patt, Sherman Oaks, CA (US); and Nelson L. Scarborough, Sherman Oaks, CA (US)
Assigned to TETROUS, INC., Sherman Oaks, CA (US)
Filed by TETROUS, INC., Sherman Oaks, CA (US)
Filed on Apr. 7, 2023, as Appl. No. 18/132,087.
Application 18/132,087 is a continuation of application No. 17/327,554, filed on May 21, 2021, granted, now 11,622,979.
Application 17/327,554 is a continuation of application No. 16/316,968, granted, now 11,045,499, issued on Jun. 29, 2021, previously published as PCT/US2017/041574, filed on Jul. 11, 2017.
Claims priority of provisional application 62/360,652, filed on Jul. 11, 2016.
Prior Publication US 2023/0355682 A1, Nov. 9, 2023
Int. Cl. A61K 35/32 (2015.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/70 (2006.01); A61L 27/36 (2006.01); A61L 27/44 (2006.01); A61L 27/46 (2006.01); A61L 27/50 (2006.01)

CPC A61K 35/32 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/7007 (2013.01); A61L 27/3612 (2013.01); A61L 27/365 (2013.01); A61L 27/446 (2013.01); A61L 27/46 (2013.01); A61L 27/50 (2013.01); A61L 2430/02 (2013.01)]

9 Claims

1. A fibrous composition for the treatment of a soft tissue wound, comprising:

polylactide fibers; and an oxygen generating material and/or an oxygen carrier coated on the polylactide fibers, wherein the polylactide fibers are about 1 cm to about 30 cm in length.